Hexarelin
Hexarelin is a peptide, indexed here under Growth hormone secretagogues.
Identity
| Field | Value |
|---|---|
| Classification | Peptide |
| Primary class | Growth hormone secretagogues |
| CAS registry number | 140703-51-1[1] |
| PubChem CID | 6918297[1] |
| UniProt accession | Unknown No UniProt query was run in v1. |
| Molecular formula | C47H58N12O6[1] |
| Molecular weight | 887 g/mol[1] |
| Amino-acid sequence | Unknown Not reported by the PubChem property set retrieved for this record; no sequence database query was run in v1. |
| Reported half-life | Unknown No pharmacokinetics source was retrieved in v1. PubChem does not carry half-life as a property, so this is recorded as not yet sourced rather than estimated. |
What the cited literature examines
Hexarelin is a synthetic hexapeptide. A 1994 Journal of Clinical Endocrinology and Metabolism paper reports its growth hormone-releasing activity after intravenous administration, and a 1994 Life Sciences paper reports the same activity in infant and adult subjects. A 2001 Journal of Clinical Endocrinology and Metabolism paper compares the endocrine activities of ghrelin, a natural growth hormone secretagogue, with synthetic agents in humans.
The retrieved set also contains cardiac endpoints independent of growth hormone: a 1999 Endocrinology paper on growth hormone-independent cardioprotective effects in the rat, and a 2002 Journal of Endocrinology paper on H9c2 cardiomyocyte cell proliferation.
[3, 4, 5, 6, 7]Reported mechanism
A synthetic growth hormone secretagogue; the retrieved literature additionally reports cardiac effects described as growth hormone-independent.
[5, 6]Stated in the titles of the cited 2001 Journal of Clinical Endocrinology and Metabolism and 1999 Endocrinology papers.
Targets named in the cited records: growth hormone secretagogue receptor.
FDA application register
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.[2]
Scope statement: this records the result of a single automated query against the openFDA drugsfda endpoint on the stated date. It is not legal advice and is not a jurisdiction-by-jurisdiction legality assessment.
Retrieved 2026-10-09.
Amounts reported in the cited literature
Unknown. No retrieved record in this dataset states an amount, so none is shown. Where an amount is recorded it is what a named study reported administering in its own stated model, in the past tense, and is not a protocol.
No study-reported dose was taken from a source read in v1. Literature-reported values are only recorded where the retrieved citation metadata states the figure.
Adverse effects reported in the cited literature
Unknown. No retrieved record in this dataset reports an adverse effect for this compound, so no row is shown. Absence of a row records the absence of a retrieved report, nothing more.
No adverse-effect row was taken from a source read in v1. Rows are only recorded with the study model named and the reporting citation attached.
Other names
Hexarelin appears under these other names in the cited records or in common usage. Each one resolves to this page rather than to a separate page of its own.
- examorelin
Where this page sits
Research records
Cited research records for Hexarelin, each with its identifier, the publication type it is indexed as, and the study model stated by its assigned subject headings.
Compounds indexed next to it
- Ipamorelin — Growth hormone secretagogues
- GHRP-6 — Growth hormone secretagogues
- AOD9604 — Growth hormone secretagogues
- Ibutamoren — Growth hormone secretagogues
Named targets in the cited records
Class page: Growth hormone secretagogues. Full index: all indexed compounds.
Questions this page answers
What does the cited literature examine for Hexarelin?
Hexarelin is a synthetic hexapeptide. A 1994 Journal of Clinical Endocrinology and Metabolism paper reports its growth hormone-releasing activity after intravenous administration, and a 1994 Life Sciences paper reports the same activity in infant and adult subjects.
Which class is Hexarelin indexed under?
Hexarelin is indexed under Growth hormone secretagogues. Growth hormone secretagogues are compounds that act at the growth hormone secretagogue receptor, the receptor for ghrelin, rather than at the growth hormone releasing hormone receptor.
What does the FDA application register show for Hexarelin?
A query of the FDA Drugs@FDA application register on 2026-10-09 returned no application records for this compound name. This compound is not approved by the FDA for human use.
Sources
- PubChem Compound Summary for CID 6918297, Examorelin. PubChem, National Library of Medicine (2026). pubchem:6918297
- Drugs@FDA application register query for this compound, no application records returned. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:hexarelin
- Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab (1994). pmid:8126144
- GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci (1994). pmid:7910650
- Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab (2001). pmid:11238504
- Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology (1999). pmid:10465272
- Natural (ghrelin) and synthetic (hexarelin) GH secretagogues stimulate H9c2 cardiomyocyte cell proliferation. J Endocrinol (2002). pmid:12379504
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.